Vall d'Hebron Institute of Research, Galatea Clinic
Also known as: David Garcia-Dorado | Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron | Department of Oncology, Hospital Universitario Vall d´Hebron | Francesc Bosch, MD | Hospital Universitario Vall d´Hebron | HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA | HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA | Hospital Universitari Vall d'Hebron, Barcelona | IOB Institute of Oncology, Vall d´Hebron Institute of Oncology (VHIO) | Liver Unit, Department of Internal Medicine, Hospital Universitario Vall d´Hebron | Medical Oncology Department, Vall d'Hebron Institute of Oncology, CIBERONC | Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital Campus | University Hospital of Vall d'Hebron | Vall de Hebron, Barcelona, Spain | Vall d'Hebron Institut de Recerca (VHIR) | Vall d'Hebron institute of oncology (VHIO), Catalan institute of oncology (Hospitalet) (ICO) | Vall d'Hebron Institute of Research, Galatea Clinic | Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain | Vall d'Hebron University Hospital (HUVH) | VHIO (Vall d'Hebron Institute of Oncology)
Highest phase reached
Phase 4
First clinical trial
Jul 1, 2007Last known activity
Sep 13, 2024
Timeline
1990s
- Jan 1, 1994
Vall d'Hebron Institute of Research, Galatea Clinic— Founded
Drugs by trial phase (34 distinct, 16 trials)
Phase 4 (4 own, 0 via acquisition)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (26 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Acute Coronary Syndrome
- Adenocarcinoma, Follicular
- Biliary Tract Neoplasms
- Carcinoma
- Carcinoma, Papillary
- Cholangiocarcinoma
- Communicable Diseases
- Endocrine Gland Neoplasms
- Infarction
- Infections
- Klatskin Tumor
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Mental Disorders
- Myocardial Infarction
- Neoplasms
- Neuroendocrine Tumors
- Pancreatic Neoplasms
- Paraganglioma
- Pheochromocytoma
- Pneumonia
- Pneumonia, Viral
- Problem Behavior
- Thyroid Cancer, Papillary
- Thyroid Carcinoma, Anaplastic
- Thyroid Diseases
- Thyroid Neoplasms
- Viremia
Recent trials (17)
- NCT06235216OfficialPhase 2Sep 13, 2024
- NCT05582031Study chairPhase 2Jan 31, 2023
- NCT05582031OfficialPhase 2Jan 31, 2023
- NCT05525286Overall official - principal investigatorPhase 1/Phase 2Mar 31, 2022
- NCT04400474Study chairPhase 2Oct 31, 2020
- NCT04378023Overall official - principal investigatorPhase 4Apr 24, 2020
- NCT04335305Study chairPhase 2Apr 14, 2020
- NCT04178798Overall official - principal investigatorPhase 3Dec 9, 2019
- NCT03818997Study chairPhase 2Aug 31, 2019
- NCT04018261Overall official - principal investigatorPhase 1/Phase 2Jul 4, 2019
- NCT03986294CollaboratorPhase 2Jul 1, 2019
- NCT03753919Study chairPhase 2Apr 2, 2019
- NCT03809897Overall official - principal investigatorPhase 4Jan 31, 2019
- NCT03786484CollaboratorPhase 1Oct 1, 2017
- NCT04756310Overall official - principal investigatorN/ANov 30, 2014
Details
- Founded
- Barcelona, ES Jan 1, 1994
- Last known activity
- Sep 13, 2024